In litigation filed in early 2026, a major GLP-1 manufacturer alleged that testing of compounded injectable semaglutide products found impurity levels as high as 86%, with compounded oral formulations containing impurities as high as 75%
These combined effects typically result in reduced caloric intake and subsequent weight loss, with clinical trials demonstrating weight reductions that vary by populationapproximately 15% in people without diabetes (STEP 1) and 10% in those with type 2 diabetes (STEP 2) over 68 weeks
While these treatments are effective, they are not suitable for everyone, particularly those with certain rare genetic disorders or some health conditions
Its prevalence remains to be determined
Bartok A, Fehr K, Bodor A, Rkosi K, Tth GK, Kvr KE et al (2015) An engineered scorpion toxin analogue with improved K V 1.3 selectivity displays reduced conformational flexibility